DDInter411 DDInter1652
A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Clonazepam {u} (Compound) resembles {v} (Compound) Cloxazolam
Clonazepam {u} (Compound) resembles {v} (Compound) Diazepam
Clonazepam {u} (Compound) treats {v} (Disease) epilepsy syndrome
Clonazepam {u} (Compound) binds {v} (Gene) NAT2
Clonazepam {u} (Compound) palliates {v} (Disease) multiple sclerosis
Clonazepam {u} (Compound) is included by {v} (Pharmacologic Class) Benzodiazepines
Clonazepam {u} (Compound) causes {v} (Side Effect) Increased appetite
Clonazepam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Clonazepam {u} may cause a minor interaction that can limit clinical effects when taken with {v} Theophylline
Clonazepam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Clonazepam (Compound) resembles Cloxazolam (Compound)
Clonazepam (Compound) resembles Diazepam (Compound)
Clonazepam (Compound) treats epilepsy syndrome (Disease)
Clonazepam (Compound) binds NAT2 (Gene)
Clonazepam (Compound) palliates multiple sclerosis (Disease)
Clonazepam (Compound) is included by Benzodiazepines (Pharmacologic Class)
Clonazepam (Compound) causes Increased appetite (Side Effect)
Clonazepam may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Clonazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept